Research Article

Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial

Table 2

Adverse events during follow-up.

Adverse eventTreatment group (n = 90)Control group (n = 90)P

Overall prevalence51(56.7)47(52.2)0.549
Fatigue4(4.4)2(2.2)0.678
Fever3(3.3)2(2.2)1
Diarrhea7(7.8)5(5.6)0.55
Abdominal pain9(10.0)11(12.2)0.635
Dyspepsia10(11.1)8(8.9)0.619
Nausea6(6.7)9(10.0)0.418
Abnormal CBC12(13.3)10(11.1)0.649
Serious adverse event0(0)0(0)-
Any other complains18(20.0)13(14.4)0.324

Note: values in parentheses are percentages. Abnormal CBC was defined as one or more than one of complete blood counts (CBC) were abnormal. Any other complains include cough, headache, itching, dizziness, arthralgia, etc.